Virtual Library
Start Your Search
Panagiotis Nikolopoulos
Author of
-
+
EP1.01 - Advanced NSCLC (ID 150)
- Event: WCLC 2019
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Advanced NSCLC
- Presentations: 1
- Now Available
- Moderators:
- Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
-
+
EP1.01-69 - Safety and Efficacy of Percutaneous Computed Tomography-Guided Thermal Ablation of Non-Small Cell Lung Cancer Metastases (Now Available) (ID 1147)
08:00 - 18:00 | Author(s): Panagiotis Nikolopoulos
- Abstract
Background
Percutaneous computed tomography-guided (CT-guided) thermal ablation is a minimally invasive method for the treatment of adrenal metastases, painful bone metastases and liver metastases originating from non-small cell lung cancer (NSCLC). We aimed to further evaluate the safety and efficacy of CT-guided radiofrequency ablation (RFA) and microwave ablation (MWA) in the management of metastases in a real-life cohort of NSCLC patients.
Method
The medical records of 142 patients with metastatic NSCLC (71, 32 and 40 patients with adrenal metastases, painful bone metastases and liver metastases, respectively) treated with CT-guided RFA or MWA were retrospectively studied. The efficacy of thermal ablation was evaluated by post-ablation imaging. For painful bone metastases, palliation was assessed by the Brief Pain Inventory (BPI) score.
Result
Technical success of CT-guided thermal ablation was 100%. No major complications occurred. Among patients with adrenal metastases treated with RFA or MWA, local recurrence was observed in 17.1% and 19.4% of cases at 1-year follow up, respectively. In patients with painful bone metastases, significant pain relief was noted after thermal ablation (p<0,001). Local recurrence was observed in 3.3% of cases with liver metastases at 1-year follow-up.
Conclusion
CT-guided RF and MW ablation is a safe and effective local treatment for the management of adrenal, bone and liver metastases from NSCLC. For painful bone metastases RF ablation provides significant pain relief.
-
+
EP1.11 - Screening and Early Detection (ID 201)
- Event: WCLC 2019
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Screening and Early Detection
- Presentations: 1
- Now Available
- Moderators:
- Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
-
+
EP1.11-03 - Diagnostic Evaluation of Patients with Solitary Pulmonary Nodules in a Tertiary Referral Center (Now Available) (ID 1145)
08:00 - 18:00 | Author(s): Panagiotis Nikolopoulos
- Abstract
Background
Management of patients with Solitary Pulmonary Nodules (SPN) is primarily targeted at achieving an early diagnosis and treatment of all malignant nodules. We herein aimed to assess the adherence of pulmonologists to current clinical practice guidelines for SPN evaluation in a tertiary referral center for thoracic diseases.
Method
The medical records of 64 patients with SPN, diagnosed and treated at Sotiria Hospital for Chest Diseases from January 2017 to September 2018 were retrospectively reviewed. Following analysis of the clinical features and imaging characteristics of all cases, the probability of malignancy was evaluated, and the management approach followed by pulmonologists was compared to the approach suggested by issued guidelines.
Result
We observed a tendency by pulmonologists to monitor all SPN irrespective of size, density and likelihood of malignancy and reassess them at an earlier time than recommended by guidelines. Use of PET/CT in solid nodules > 8 mm of very low (50%) and high (80%) probability of malignancy was also observed, despite lack of a clear indication of PET/CT in the above patients’ groups. Conventional bronchoscopy was performed in 81% of patients with a SPN of > 8 mm with intermediate and high probability of malignancy, even though this is not typically recommended. A low-dose protocol was applied in the majority of SPN cases monitored by computed tomography, in accordance with guidelines. Malignancy was diagnosed in 42/64 patients.
Conclusion
Pulmonologists in real-world practice may adopt a more "aggressive" management approach towards patients with SPN, so as to exclude the possibility of an underlying malignancy.
